At a glance
ClinicalIndex Comparison RecordN/ACompleted· 312 enrolled
Drug / intervention
Bimatoprost 0.01%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Bimatoprost 0.01% in the Clinical Setting
In Brief
An observational study evaluating Bimatoprost 0.01% for Glaucoma, Primary Open Angle and Ocular Hypertension. Completed, enrolled 312 participants across 1 site.
Detailed Summary
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Primary Open Angle, Ocular Hypertension
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartMay 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedMar 20, 2013
Enrollment StartMay 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.3 years ago
Interventions
Bimatoprost 0.01%drug
One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.